Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems

Introduction: Intravenously injected nanoparticles, like any other foreign pathogen that enters the body, encounter multiple lines of defense intended to neutralize and eliminate the invading substance. Adsorption of plasma proteins on the nanoparticle surface is the first barrier of defense, which could lead to physical changes in the formulation, such as aggregation and charge neutralization, biochemical activation of defense cascades, and trigger elimination by multiple types of phagocytic cell. Areas covered: In this review, recent knowledge on the mechanisms that govern the interactions of nanoparticles (micelles, liposomes, polymeric and inorganic nanoparticles) with plasma proteins is discussed. In particular, the role of the nanoparticle surface properties and protective polymer coating in these interactions is described. The mechanisms of protein adsorption on different nanoparticles are analyzed and the implications on the clearance, toxicity and efficacy of drug delivery are discussed. The review provides readers with the biological insight into the plasma/blood interactions of nanoparticles. Expert opinion: The immune recognition of nanoparticles can seriously affect the drug delivery efficacy and toxicity. There is at present not enough knowledge on the mechanisms that dictate the nanoparticle immune recognition and stability in the biological milieu. Understanding the mechanisms of recognition will become an important part of nanoparticle design.

[1]  E Froehlich,et al.  Dendrimers bind human serum albumin. , 2009, The journal of physical chemistry. B.

[2]  Michael J Sailor,et al.  Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. , 2008, Angewandte Chemie.

[3]  J. Weinstein,et al.  Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. , 1980, Journal of lipid research.

[4]  R. Juliano,et al.  Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. , 1982, Biochimica et biophysica acta.

[5]  Ick Chan Kwon,et al.  The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[7]  L. Kobzik,et al.  Lung macrophage uptake of unopsonized environmental particulates. Role of scavenger-type receptors. , 1995, Journal of immunology.

[8]  Ralph Weissleder,et al.  Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. , 2002, Academic radiology.

[9]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[10]  Robert Langer,et al.  Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. , 2009, Biomaterials.

[11]  Hideyoshi Harashima,et al.  Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.

[12]  J. Brash,et al.  Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. , 2001, Biochimica et biophysica acta.

[13]  Thomas Vorup-Jensen,et al.  Curvature of Synthetic and Natural Surfaces Is an Important Target Feature in Classical Pathway Complement Activation , 2010, The Journal of Immunology.

[14]  Karl Fischer,et al.  Evaluation of nanoparticle aggregation in human blood serum. , 2010, Biomacromolecules.

[15]  Ronald J Moore,et al.  Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. , 2004, Analytical chemistry.

[16]  Isabelle Raynal,et al.  Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10 , 2004, Investigative radiology.

[17]  G. Borchard,et al.  The Role of Serum Complement on the Organ Distribution of Intravenously Administered Poly (methyl methacrylate) Nanoparticles: Effects of Pre-Coating with Plasma and with Serum Complement , 1996, Pharmaceutical Research.

[18]  Ruth Nussinov,et al.  Nanoparticle-induced vascular blockade in human prostate cancer. , 2010, Blood.

[19]  T. Fujita,et al.  The lectin‐complement pathway – its role in innate immunity and evolution , 2004, Immunological reviews.

[20]  I. Maridonneau-Parini,et al.  The human macrophage mannose receptor is not a professional phagocytic receptor , 2005, Journal of leukocyte biology.

[21]  D. Falcone Fluorescent Opsonization Assay: Binding of Plasma Fibronectin to Fibrin‐Derivatized Fluorescent Particles Does Not Enhance Their Uptake by Macrophages , 1986, Journal of leukocyte biology.

[22]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[23]  K. Williams,et al.  Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. , 1989, The Journal of biological chemistry.

[24]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  D. Devine,et al.  Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. , 1998, Archives of biochemistry and biophysics.

[26]  Sara Linse,et al.  Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. , 2007, Angewandte Chemie.

[27]  W. J. Duncanson,et al.  ApJ, in press , 1999 .

[28]  R. Müller,et al.  Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. , 2005, International journal of pharmaceutics.

[29]  R. Müller,et al.  Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[31]  T. Rabilloud Two‐dimensional gel electrophoresis in proteomics: Old, old fashioned, but it still climbs up the mountains , 2002, Proteomics.

[32]  Y. Kurihara,et al.  Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. , 1993, The Journal of biological chemistry.

[33]  S. Davis,et al.  Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. , 1991, Biochemical and biophysical research communications.

[34]  P. Couvreur,et al.  Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.

[35]  Warren C W Chan,et al.  Mediating tumor targeting efficiency of nanoparticles through design. , 2009, Nano letters.

[36]  J. Chen,et al.  Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. , 2010, Journal of biomedical nanotechnology.

[37]  P. Cullis,et al.  Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. , 1998, Advanced drug delivery reviews.

[38]  V. Kolb‐Bachofen Uptake of toxic silica particles by isolated rat liver macrophages (Kupffer cells) is receptor mediated and can be blocked by competition. , 1992, The Journal of clinical investigation.

[39]  J. Kamps,et al.  The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. , 2005, Biochemical and biophysical research communications.

[40]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[41]  B. Pati,et al.  Colorimetric assay method for determination of the tannin acyl hydrolase (EC 3.1.1.20) activity. , 2001, Analytical biochemistry.

[42]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[43]  L. Vroman,et al.  Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. , 1980, Blood.

[44]  G. Kenner,et al.  Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. , 2007, Biochimica et biophysica acta.

[45]  H. Merkle,et al.  Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. , 2003, Biomaterials.

[46]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Sara Linse,et al.  The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.

[48]  Y. Barenholz,et al.  The Role of Organ Vascularization and Lipoplex-Serum Initial Contact in Intravenous Murine Lipofection* , 2003, Journal of Biological Chemistry.

[49]  C. Allen,et al.  Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[50]  P. Cullis,et al.  β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*) , 1995, The Journal of Biological Chemistry.

[51]  M. Kamihira,et al.  Protamine-modified DDAB lipid vesicles promote gene transfer in the presence of serum. , 2001, Journal of biochemistry.

[52]  V. Kolb-Bachofen,et al.  Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. , 1993, Biochimica et biophysica acta.

[53]  M. Morandi,et al.  Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.

[54]  S. Davis,et al.  An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. , 1993, Biochimica et biophysica acta.

[55]  Nancy A Monteiro-Riviere,et al.  Mechanisms of quantum dot nanoparticle cellular uptake. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[56]  A. Curtis,et al.  Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. , 2004, Biomaterials.

[57]  Benoit Nemery,et al.  Ultrafine particles affect experimental thrombosis in an in vivo hamster model. , 2002, American journal of respiratory and critical care medicine.

[58]  C. Hunt,et al.  Murine plasma fibronectin depletion after intravenous injection of liposomes , 1987 .

[59]  Esther H Chang,et al.  Does a targeting ligand influence nanoparticle tumor localization or uptake? , 2008, Trends in biotechnology.

[60]  John W. Earl,et al.  Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases , 2007, European Journal of Clinical Pharmacology.

[61]  P. S. Appukuttan,et al.  Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. , 2003, Molecular immunology.

[62]  Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. , 1992, Blood.

[63]  Ji-Ho Park,et al.  Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. , 2009, Biomaterials.

[64]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[65]  P. Dubin,et al.  Binding of bovine serum albumin to heparin determined by turbidimetric titration and frontal analysis continuous capillary electrophoresis. , 2001, Analytical biochemistry.

[66]  G. Oberdörster,et al.  Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.

[67]  T. Yen,et al.  Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug , 2010, Nanotechnology.

[68]  Iseult Lynch,et al.  Protein-nanoparticle interactions: What does the cell see? , 2009, Nature nanotechnology.

[69]  S. Gordon,et al.  Scavenger receptors: diverse activities and promiscuous binding of polyanionic ligands. , 1998, Chemistry & biology.

[70]  Mark E. Davis,et al.  Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[71]  J. Kamps,et al.  Receptor versus non-receptor mediated clearance of liposomes. , 1998, Advanced drug delivery reviews.

[72]  R. Weissleder,et al.  Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.

[73]  F M Muggia,et al.  Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. , 1998, Journal of the National Cancer Institute.

[74]  H. Harashima,et al.  Identification of proteins mediating clearance of liposomes using a liver perfusion system. , 1998, Advanced drug delivery reviews.

[75]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[76]  Mitsuru Hashida,et al.  Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. , 2007, International journal of pharmaceutics.

[77]  Michael V Sefton,et al.  Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. , 2004, Biomaterials.

[78]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[79]  D. V. Von Hoff,et al.  A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon , 1994, American journal of clinical oncology.

[80]  Darren J. Martin,et al.  Differential plasma protein binding to metal oxide nanoparticles , 2009, Nanotechnology.

[81]  M. Hashida,et al.  Important role of serum proteins associated on the surface of particles in their hepatic disposition. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[82]  J. E. Doran,et al.  A Critical Assessment of Fibronectin's Opsonic Role for Bacteria and Microaggregates , 1983, Vox sanguinis.

[83]  R. Müller,et al.  Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. , 2005, Biomaterials.

[84]  D. Scherman,et al.  Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[85]  B. Nemery,et al.  Acute Toxicity and Prothrombotic Effects of Quantum Dots: Impact of Surface Charge , 2008, Environmental health perspectives.

[86]  R. Müller,et al.  Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. , 2000, International journal of pharmaceutics.

[87]  I. Schousboe beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. , 1985, Blood.

[88]  V. Werth,et al.  Intravenously Administered Lecithin Liposomes: A Synthetic Antiatherogenic Lipid Particle , 2015, Perspectives in biology and medicine.

[89]  P. Cullis,et al.  Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. , 1992, The Journal of biological chemistry.

[90]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[91]  Rassoul Dinarvand,et al.  PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. , 2008, International journal of pharmaceutics.

[92]  P Couvreur,et al.  In vitro evaluation of nanoparticles spleen capture. , 1999, Life sciences.

[93]  R. Weissleder,et al.  Hybrid PET-optical imaging using targeted probes , 2010, Proceedings of the National Academy of Sciences.

[94]  A. Bangham,et al.  NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. , 1964, Journal of molecular biology.

[95]  W. Goldman,et al.  Fungal stealth technology. , 2008, Trends in immunology.

[96]  G. Scherphof,et al.  The role of beta2-glycoprotein I in liposome-hepatocyte interaction. , 2004, Biochimica et biophysica acta.

[97]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[98]  S. Moghimi,et al.  Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol‐rich liposomes , 1988, FEBS letters.

[99]  M. Benet,et al.  Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[100]  Kwangmeyung Kim,et al.  Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[101]  H. Tsukada,et al.  Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. , 1996, Biochimica et biophysica acta.

[102]  H. Iwata,et al.  Complement activation by polymers carrying hydroxyl groups. , 2009, ACS applied materials & interfaces.

[103]  S Gordon,et al.  Macrophage receptors and immune recognition. , 2005, Annual review of immunology.

[104]  R. Gurny,et al.  An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.

[105]  J. Brash,et al.  Identification of apolipoprotein A-I as a major adsorbate on biomaterial surfaces after blood or plasma contact. , 2002, Biomaterials.

[106]  P. Legrand,et al.  Polyester-Poly(Ethylene Glycol) Nanoparticles Loaded with the Pure Antiestrogen RU 58668: Physicochemical and Opsonization Properties , 2003, Pharmaceutical Research.

[107]  T. Ishida,et al.  Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[108]  Michael J Sailor,et al.  Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. , 2009, Small.

[109]  H. Sano,et al.  A novel type of binding specificity to phospholipids for rat mannose‐binding proteins isolated from serum and liver , 1997, FEBS letters.

[110]  Jack F Douglas,et al.  Interaction of gold nanoparticles with common human blood proteins. , 2010, ACS nano.

[111]  S. Nagata,et al.  Identification of Tim4 as a phosphatidylserine receptor , 2007, Nature.

[112]  Barbara Klajnert,et al.  Haemolytic activity of polyamidoamine dendrimers and the protective role of human serum albumin , 2010, Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[113]  K. Mattison,et al.  Complex Formation between Bovine Serum Albumin and Strong Polyelectrolytes: Effect of Polymer Charge Density , 1998 .

[114]  J. Ruysschaert,et al.  Identification of human plasma proteins that bind to cationic lipid/DNA complex and analysis of their effects on transfection efficiency: implications for intravenous gene transfer. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[115]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[116]  Parag Aggarwal,et al.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[117]  K. Higaki,et al.  Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.

[118]  D Needham,et al.  Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. , 1992, Biochimica et biophysica acta.

[119]  A. Maitra,et al.  Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. , 2000, International journal of pharmaceutics.

[120]  S. K. Sundaram,et al.  Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[121]  S Moein Moghimi,et al.  Complement: alive and kicking nanomedicines. , 2009, Journal of biomedical nanotechnology.

[122]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[123]  Rainer H Müller,et al.  Functional groups on polystyrene model nanoparticles: influence on protein adsorption. , 2003, Journal of biomedical materials research. Part A.